Specific peptides from both MAP30 and Momordin, that have been shown to reduce hypertension in a rat model and to competitively inhibit angiotensin-converting enzyme (ACE), a homolog of ACE2 [35] and the key receptor for SARS-CoV-2, have the potential to block viral entry. Here, ACE is linked to hypertensive disorder.